We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Lawmakers Keep Merck, Schering-Plough In Hot Seat

Law360 (February 12, 2008, 12:00 AM EST) -- Messages posted on a Web site frequented by pharmaceutical sales representatives have led two congressmen to further question the handling of a study by Merck & Co. Inc. and Schering-Plough Corp. for their cholesterol drug Vytorin.

In a letter Monday, Reps. John Dingell (D-Mich.) and Bart Stupak (D-Mich.) questioned why anonymous posters on cafepharma.com were talking about the controversial Enhance trial for Vytorin nine months before the companies had released data about the study.

“These Web site entries are obviously troubling and raise again the question...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.